Enric Pedrol
Overview
Explore the profile of Enric Pedrol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
403
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pretel Y, Noblia L, Tango A, Pedrol E
Rev Esp Geriatr Gerontol
. 2020 Nov;
56(1):54-55.
PMID: 33223265
No abstract available.
2.
Bano M, Moren C, Barroso S, Juarez D, Guitart-Mampel M, Gonzalez-Casacuberta I, et al.
Front Genet
. 2020 Jun;
11:497.
PMID: 32528527
Mitochondrial genome has been used across multiple fields in research, diagnosis, and toxicogenomics. Several compounds damage mitochondrial DNA (mtDNA), including biological and therapeutic agents like the human immunodeficiency virus (HIV)...
3.
Pedrol E, Caro-Murillo A, Castano M, Riera M, Olalla J, Domingo P, et al.
HIV Clin Trials
. 2015 Mar;
16(1):43-8.
PMID: 25777189
Objectives: Our aim is to describe the impact of emtricitabine (FTC)/tenofovir (TDF) versus other nucleoside reverse transcriptase inhibitor (NRTIs)-based regimens on renal function of human immunodeficiency virus (HIV) naïve patients...
4.
Polo Rodriguez R, Galindo Puerto M, Duenas C, Gomez Candela C, Estrada V, Villar N, et al.
Enferm Infecc Microbiol Clin
. 2014 Sep;
33(1):40.e1-40.e16.
PMID: 25176009
Objective: This consensus document is an update of metabolic disorders and cardiovascular risk (CVR) guidelines for HIV-infected patients. Methods: This document has been approved by an expert panel of GEAM,...
5.
Polo Rodriguez R, Galindo Puerto M, Duenas C, Gomez Candela C, Estrada V, Villar N, et al.
Enferm Infecc Microbiol Clin
. 2014 Aug;
33(1):41-7.
PMID: 25096166
The importance of the metabolic disorders and their impact on patients with HIV infection requires an individualized study and continuous updating. HIV patients have the same cardiovascular risk factors as...
6.
Pedrol E, Viciana P, Arranz A, Pasquau J, Deig E, Tasias M
Rev Esp Quimioter
. 2014 Jun;
27(2):93-7.
PMID: 24940888
Survey in 349 HIV infected subjects in 19 Spanish Hospitals in 2010-2011, to assess the reasons for antiretroviral treatment change. Simplification was the most frequent reason for change (37%), followed...
7.
Polo R, Pedrol E, Miro O
Enferm Infecc Microbiol Clin
. 2014 Jan;
32(4):274-5.
PMID: 24468628
No abstract available.
8.
Blanco J, Caro-Murillo A, Castano M, Olalla J, Domingo P, Arazo P, et al.
HIV Clin Trials
. 2013 Oct;
14(5):204-15.
PMID: 24144897
Objectives: Current antiretroviral guidelines state that being older than 50 to 55 years of age is an indication to start antiretroviral therapy (ART), regardless of CD4 status. However, no references...
9.
Pedrol E, Lopez-Bernaldo J, Ruiz S, Hevia H, Ledesma F
Rev Esp Quimioter
. 2013 Jul;
26(2):103-7.
PMID: 23817646
Introduction: In 2009 a deep change in ARV treatment took place in Spain with the introduction of new ARV drugs. The principal objective of the study was to determine the...
10.
Estrada V, Geijo P, Fuentes-Ferrer M, Alcalde M, Rodrigo M, Galindo M, et al.
BMC Womens Health
. 2011 Aug;
11:36.
PMID: 21816091
Background: Information concerning lipid disturbances in HIV-infected women on antiretroviral therapy (ART) is scarce. The objective of the study is to describe the lipid profile in a large cohort of...